Standout Papers

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias 2012 2026 2016 2021 512
  1. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012)
    Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine
  2. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017)
    Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 35 from Science/Nature 69 standout
Sub-graph 1 of 20

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
2024 Standout
9 intermediate papers

Works of Michael J. Mauro being referenced

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
2012 Standout
A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings
2010
and 3 more

Author Peers

Author Last Decade Papers Cites
Michael J. Mauro 3817 2964 2059 230 5.1k
Philipp le Coutre 3452 2631 1737 153 4.7k
Gabriel Étienne 5151 4198 2425 108 6.0k
Gianantonio Rosti 5567 4528 2663 211 6.7k
Charles Chuah 3405 2621 1554 107 4.5k
Joëlle Guilhot 3377 2957 1703 128 4.8k
François‐Xavier Mahon 5480 4381 2537 204 6.8k
Norbert Gattermann 5499 3628 1104 253 7.0k
Susan O’Brien 4258 3395 1909 73 5.7k
Susanne Saußele 3066 2641 1373 121 3.7k
Mary Frances McMullin 4110 4274 1445 214 7.3k

All Works

Loading papers...

Rankless by CCL
2026